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Psoriasis vulgaris is a chronic inflammatory skin disease with an immune-genetic back-
ground. It has been reported as an independent risk factor for coronary heart disease
(CHD) in the United States and Europe. The purpose of this study was to investigate the
association between psoriasis and CHD in a hospital-based population in Japan.
Methods
For 113,065 in-hospital and clinic patients at our institution between January 1, 2011 and
January 1, 2013, the diagnostic International Classification of Diseases (ICD)-10 codes for
CHD, hypertension, dyslipidemia, diabetes, and psoriasis vulgaris were extracted using the
medical accounting system and electronic medical record, and were analyzed.
Results
The prevalence of CHD (n = 5,167, 4.5%), hypertension (n = 16,476, 14.5%), dyslipidemia
(n = 9,236, 8.1%), diabetes mellitus (n = 11,555, 10.2%), and psoriasis vulgaris (n = 1,197,
1.1%) were identified. The prevalence of CHD in patients with hypertension, dyslipidemia,
diabetes, and psoriasis vulgaris were 21.3%, 22.2%, 21.1%, and 9.0%, respectively. In 1,197
psoriasis patients, those with CHDwere older, more likely to be male, and had more number
of the diseases surveyed by ICD-10 codes. Multivariate analysis showed that psoriasis vulga-
ris was an independent associated factor for CHD (adjusted odds ratio [OR]: 1.27; 95% confi-
dence interval [CI]: 1.01–1.58; p = 0.0404) along with hypertension (adjusted OR: 7.78; 95%
CI: 7.25–8.36; p < 0.0001), dyslipidemia (adjusted OR: 2.35; 95% CI: 2.19–2.52; p < 0.0001),
and diabetes (adjusted OR: 2.86; 95% CI: 2.67–3.06; p < 0.0001).
Conclusion
Psoriasis vulgaris was independently associated with CHD in a hospital-based population
in Japan.
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Introduction
Psoriasis vulgaris is a chronic inflammatory skin disease with an immune-genetic background.
Although its pathogenesis is not fully understood, there is solid evidence of a susceptibility
locus in the human leukocyte antigen region [1, 2]. Genetic polymorphisms in the vascular
endothelial growth factor (VEGF) gene may also contribute to psoriasis and differ between
Caucasians and Asians [3]. Psoriasis is common in Caucasians but is rare in Africans [4, 5]. In
Asians, psoriasis is less common. The prevalence of psoriasis vulgaris is 0.34% of the general
population in Japan [6]. This prevalence is lower than that of the general population in the
United States and Europe (2.0–4.0%) [7–9].
Systemic low-grade inflammation may be involved in the pathogenesis of psoriasis [10, 11].
Patients with psoriasis vulgaris typically have a higher prevalence of dyslipidemia, hyperten-
sion, smoking, and obesity compared to those without psoriasis [12]. These comorbidities
overlap with the risk factors of coronary heart disease (CHD) [12–15], although the precise
mediated mechanisms linking psoriasis and CHD have not been clear.
Many studies in the United States and Europe have shown that psoriasis is an independent
risk factor for CHD and cardiovascular events [16–24] or cardiovascular mortality [25]; how-
ever, in contrast, other studies concluded that that psoriasis is not an independent risk factor
for coronary atherosclerosis and acute cardiovascular events [26–30]. These conflicting results
may be because of the differences in the study design, severity of psoriasis, or confounders and
effect modifiers, such as psoriatic arthritis [31]. In Japan, the relationship between psoriasis
vulgaris and CHD has almost never been studied. One reason for this is the rarity of psoriasis
vulgaris in Japanese patients [6]. Considering that an immune-genetic background strongly
affects the prevalence of psoriasis and the common underlying causes such as systemic low-
grade inflammation, the association between psoriasis and CHD should also be apparent in
Japanese patients. The aims of this study were to investigate the relationship between psoriasis
vulgaris and CHD in a hospital-based population in Japan.
Methods
Patient population
The medical accounting system and electronic medical record (EMR) data of all clinic and in-hos-
pital patients of all ages at our institution between January 1, 2011 and January 1, 2013 were studied
retrospectively. From the EMR data, we extracted patients’ data, including their name, age, and sex
by each disease, i.e., psoriasis vulgaris (International Classification of Diseases [ICD]-10 code
L40.0), hypertension (ICD-10 codes I10, I11, I12, I13, I14, and I15), dyslipidemia (ICD-10 code
E78), diabetes mellitus (ICD-10 codes E10, E11, E12, E13, and E14), and CHD. CHD included
ischemic heart disease, myocardial infarction (acute, sub-acute, or old, i.e., ICD-10 codes I21, I22,
and I25.2, respectively), and angina pectoris (I20). Each disease was regarded as present when the
diagnoses were recorded in the hospital charts. The total number of in-hospital and clinic patients
at our institution was determined by the medical accounting system. The research protocol was
approved by the institutional review board of Kitano Hospital according to the ethical guidelines of
the 1975 Declaration of Helsinki (P15-06-005). Since this is a retrospective study, the consent was
not obtained and patient records/information was anonymized and de-identified prior to analysis.
Statistics
Continuous variables are expressed as the mean ± standard deviation. Mean numbers of risk
factors are expressed as the mean and 95% confidence interval (CI). In comparisons of the
baseline characteristics of the study population, the chi square test was used for categorical
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variables and the Wilcoxon rank sum test was used for continuous variables when appropriate.
Differences in categorical variables among two or more groups were analyzed using the
Cochran-Mantel-Haenszel test. Associations between the diseases surveyed and CHD in
patients overall were analyzed using a multivariate logistic regression model, which was
adjusted for hypertension, dyslipidemia, diabetes mellitus, and psoriasis. In subgroup analysis
of patients who had at least one disease, including CHD, hypertension, dyslipidemia, diabetes,
and psoriasis, the association between factors were analyzed by using a multivariate logistic
regression model, which was adjusted for hypertension, dyslipidemia, diabetes mellitus, psoria-
sis, and sex as categorical variables and age as a continuous variable. Adjusted odds ratios
(ORs) and 95% CIs were calculated. A p value<0.05 was considered statistically significant in
all analyses. Statistical analyses were performed using JMP software, version 10 (SAS Corp.).
Results
The prevalence of CHD (n = 5,167, 4.2%), hypertension (n = 16,476, 14.5%), dyslipidemia
(n = 9,236, 8.1%), diabetes mellitus (n = 11,555, 10.2%), and psoriasis vulgaris (n = 1,197,
1.0%) were identified (Table 1). The prevalence of CHD in patients with hypertension, dyslipi-
demia, diabetes, and psoriasis vulgaris were 21.3% (3,510/16,476), 22.2% (2,056/9,236), 21.1%
(2,442/11,555), and 9.0% (108/1197), respectively (Table 1).
Regardless of whether patients did or did not have psoriasis, patients with CHD had more
number of the three major diseases (hypertension, dyslipidemia, and diabetes) related to CHD
than those without CHD (p< 0.001, Table 2). In 1,197 psoriasis patients, those with CHD
were older and more likely to be male than those without CHD (p< 0.001), and they had the
highest number of the above-mentioned diseases than the other groups (p< 0.001 by the
Cochran-Mantel-Haenszel test, Table 2).
Multivariate logistic regression analysis after adjusting for hypertension, dyslipidemia, and
diabetes, and psoriasis, showed that psoriasis vulgaris was still independently associated with
CHD (adjusted OR: 1.27; 95% CI: 1.01–1.58; p = 0.0404), along with hypertension (adjusted
OR: 7.78; 95% CI: 7.25–8.36; p< 0.0001), dyslipidemia (adjusted OR: 2.35; 95% CI: 2.19–2.52;
Table 1. Factors related to coronary heart disease (CHD) among the study patients.
CHD
Total Present Absent
Variables (n = 113,065) (n = 5167) (n = 107,898)
With hypertension 16,476 (14.5%) 3,510 (21.3%) 12,966 (78.7%)
Mean age (SD) 70.7 (14.3) 75.6 (11.0) 69.4 (14.8)
Male (n, %) 8,642 (52.4%) 2,165 (61.8%) 6,477 (49.9%)
With dyslipidemia 9,236 (8.1%) 2,056 (22.2%) 7,180 (77.7%)
Mean age (SD) 70.0 (3.4) 75.3 (10.6) 68.5 (13.7)
Male (n, %) 4,293 (46.1%) 1,211 (58.9%) 3,082 (42.9)
With diabetes mellitus 11,555 (10.2%) 2,442 (21.1%) 9,113 (78.9%)
Mean age (SD) 69.7 (13.2) 74.9 (10.3) 68.3 (13.5)
Male (n, %) 6,741 (58.3%) 1,602 (65.6 5,139 (56.3)
With psoriasis 1,197 (1.0%) 108 (9.0%) 1,089 (91.0%)
Mean age (SD) 64.9 (18.1) 75.0 (12.8) 63.1 (19.0)
Male (n, %) 762 (63.6%) 81 (75.0%) 681 (62.5%)
With CHD 5,167 (4.2%)
Mean age (SD) 74.0 (12.0)
Male (n, %) 3,059 (59.2%)
doi:10.1371/journal.pone.0149316.t001
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p< 0.0001) and diabetes (adjusted OR: 2.86; 95% CI: 2.67–3.06; p< 0.0001) in an entire hospi-
tal-based population (Fig 1). We next assessed 25,799 patients who have at least one disease
including CHD, hypertension, dyslipidemia, diabetes, and psoriasis (Table A in S1 File). The
psoriasis also shows an independent association with CHD after adjustment for sex and age
(Table B in S1 File) in these patients.
Discussion
In this retrospective study, we showed the prevalence of psoriasis vulgaris in a hospital-based
population in Japan. We also determined that psoriasis vulgaris is independently associated
with CHD in these patients.
Table 2. Comparison of the characteristics in psoriasis patients with and without CHD.
With psoriasis Without psoriasis
CHD CHD
Total Present Absent Total Present Absent
Variable (n = 1,197) (n = 108) (n = 1,089) (n = 111,868) (n = 5,059) (n = 106,809)
Age (y.o., mean, SD) 64.1 ± 18.9 75.0 ± 12.8 63.1 ± 19.0 n/a 74.0 ± 12.0 n/a
Male (n, %) 762 (63.6%) 81 (75%) 681 (62.5%) n/a 2978 (58.8%) n/a
Hypertension 288 (24.0%) 81 (75.0%) 207 (19.0%) 16,188 (14.4%) 3,429 (67.7%) 12,759 (11.9%)
Dyslipidemia 231 (19.2%) 63 (58.3%) 168 (15.4%) 9,005 (8.0%) 1,993 (39.3%) 7,012 (6.5%)
Diabetes mellitus 252 (21.0%) 60 (55.5%) 192 (17.6%) 11,303 (10.1%) 2,382 (47.0%) 8,921 (8.3%)
No. of the three major
diseases#
3 73 (6.1%) 27 (25.0%) 46 (4.2%) 2,883 (2.5%) 1,066 (21.0%) 1,817 (1.7%)
2 173 (14.5%) 49 (45.4%) 124 (11.4%) 7,112 (6.3%) 1,594 (31.5%) 5,518 (5.1%)
1 204 (17.0%) 25 (23.1%) 179 (16.5%) 13,623 (12.1%) 1,418 (28.0%) 12,205 (11.4%)
0 747 (62.3%) 7 (6.5%) 740 (68.0%) 88,250 (78.8%) 981 (19.3%) 87,269 (81.7%)














#: hypertension, dyslipidemia, and diabetes mellitus, CI: conﬁdence interval, n/a: not available.
doi:10.1371/journal.pone.0149316.t002
Fig 1. Multivariate logistic regression analysis of the factors related to coronary heart disease.Data are adjusted for hypertension, dyslipidemia,
diabetes mellitus, and psoriasis.
doi:10.1371/journal.pone.0149316.g001
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Psoriasis has been associated with chronic systemic inflammation mediated by the type 1
helper T (Th1) cell [32, 33] and Th17 cell [10, 34, 35]. The Th1 cell stimulates macrophages
that secrete tumor necrosis factor α (TNF-α). Recently, there has been an increasing interest in
the Th 17 cell pathway [36] and related pro-inflammatory cytokines in psoriasis, including
interleukin (IL)-17 and IL23 [37], which induce the production of inflammatory mediators
such as IL1, IL6, IL8, and TNF-α [33]. TNF-α activates endothelium and facilitates leukocyte
invasion into surrounding tissues, resulting in the formation of infiltrated plaques, and causes
insulin resistance in endothelial cells through the p38 mitogen-activated protein kinase path-
way [38]. Chronic inflammation is associated with insulin resistance, which leads to endothe-
lial dysfunction by disturbing vasodilation through the endothelial nitric oxide synthase
pathway [39]. The contribution of genetic polymorphisms to the VEGF gene in psoriasis has
also been reported [3]. These data support the association between psoriasis and CHD through
chronic low-grade systemic inflammation and endothelial dysfunction via the overlapping
risks for CHD, as also shown in Japanese patients in the present study.
Psoriasis vulgaris has been reported to be independent risk factors for CHD in Europe and
United States [16–24]. However, a recently published study by Parisi (2015), including a cohort
of 48,523 patients with psoriasis and 208,187 controls and a greater number of predictor vari-
ables, did not find an association between psoriasis (hazard ratio [HR]: 1.02, 95%CI: 0.96–1.08)
or severe psoriasis (HR:1.29, 95%CI: 0.97–1.70) and the risk for cardiovascular events [30]. In
contrast, Dregan et al. (2014), using the same database and inception cohort design, found an
independent association between psoriasis and coronary heart disease; their point estimate of
the HR of coronary heart disease in severe psoriasis was 1.29 (95% CI: 1.01–1.64, p = 0.042).
[23]. Ogdie also reported, using similar database, that the risk of cardiovascular events was
higher in patients with psoriasis not prescribed a disease modifying anti-rheumatic drug (HR
1.08, 95%CI: 1.02–1.15) and in patients with severe psoriasis (disease modifying anti-rheumatic
drug users: HR 1.42, 95%CI: 1.17–1.73) [40]. One reason for these conflicting results may be
the inclusion of psoriatic arthritis as an independent confounder in the Parisi study [30,31].
Psoriatic arthritis is associated with psoriasis vulgaris; hence, it can be considered an effect
modifying factor that moderates the relationship between psoriasis and outcome [31]. When
psoriatic arthritis excluded, the fully adjusted HR of psoriasis and severe psoriasis was 1.46
(95%CI: 1.11–1.92) [30]. A possible association between severe psoriasis and cardiovascular
disease was reported by a systematic review of 14 epidemiologic studies [41]. However, whether
cardiovascular disease is directly associated with psoriasis remains uncertain, as many of these
studies, as well as our present study, could not exclude the possibility of inadequate adjustment
for risk factors [41].
Another reason for this inconsistency may be the study design (inception or prevalent
cohort). An inception cohort fully captures risk in case of early disease-related outcomes. How-
ever, in the setting of psoriasis and CV risk, disease duration (and thus long-term exposure to
inflammation) is related to the outcome, with increased risk of the poor outcome as the duration
increases. [17]. Thus, use of an inception cohort with short-term follow-up will result in underes-
timation of the true effect. The prevalent cohort, in contrast, better represents psoriasis patients
in the general population. Prevalent designs, however, also have limitations. [31]. The prevalent
designs may lead to underestimation of the effect through exclusion of outcomes related to mor-
tality (as in the cases of death from cardiovascular events). [23,40]. Our study design is cross-sec-
tional with one time-point observation. The cardiovascular outcomes were not evaluated but the
presence of CHD was assessed with psoriasis in the present study; hence we only addressed the
independent association (adjusted OR: 1.27; 95% CI: 1.01–1.58; p = 0.0404).
There have been reports that the long-term use of anti-hypertensive drugs and hypertension
itself are possibly associated with the development of psoriasis vulgaris [15,39,42].
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Dyslipidemia has been also closely associated with psoriasis [43], although the mechanism of
connections between psoriasis vulgaris and dyslipidemia is not clear. In another report which
analyzed Japanese psoriasis patients, the prevalence of hyperlipidemia and hypertension ran-
ged from 16.7% to 20.7% and from 22.8 to 28.5%, respectively [6], which is consistent with the
prevalence in our analysis (Table 2). Table 3 shows the ORs of CHD reported previously in
general or hospital-based population in Japan and other countries [17, 44–46]. ORs for CHD
in this study were comparable for diabetes mellitus and dyslipidemia but seemed to be high for
hypertension compared to those of the general population. The prevalence of CHD in patients
with psoriasis was 9% (95% CI: 7.38–10.62) in the present analysis. The prevalence of CHD in
the entire hospital-based population was 4.5% (95%CI: 4.44–4.69) in the present analysis,
whereas the prevalence of CHD in general population estimated by the government data was
0.71% (95%CI: 95%CI: 0.66–0.76) which is calculated from the estimated total numbers of
CHD patients (911,000) and the estimated numbers of total population (127, 435,000) in Japan
[47]. Thus, several sort of bias may exist in the hospital-based population in the present study.
Although further population-based studies are required for generalization, we showed that
psoriasis vulgaris is an independent associated factor for having CHD in the entire hospital-
based population in the present study (Fig 1) and in patients with one or more disease codes
surveyed after adjustment of age and sex (Table B in S1 File).
Study Limitations
There were several limitations in the study. First, our study did not consider patients’ smoking
status or blood tests. Smoking is a risk factor of psoriasis vulgaris [13]. Smoking may affect
both CHD and psoriasis. Therefore, smoking would be an important factor. However, it was
difficult to determine the smoking habits of all psoriasis patients because the EMR data were
retrospective and disease-specific. In addition, since the data of the EMR of the total patients
(113,065) was too large to be processed and the total number of patients was collected from the
medical accounting system instead, the age and sex of the entire cohort were unknown. It is
possible that other unknown confounding factors, including body weight and genetic back-
grounds, affected the result. Lack of these data might lead to an inadequate adjustment. In
addition, our study population did not represent the general Japanese population. Second,
diagnostic codes consistent with the diseases may have included registered codes acceptable to
the Japanese health care insurance system. There is a possibility that we overestimated or
underestimated the prevalence of these diseases. Third, our study did not demonstrate a tem-
poral relationship or dose-responsiveness. Finally, the CI of psoriasis was relatively broad (95%
CI: 1.01–1.58). Therefore, we could not conclude that psoriasis is a risk factor of CHD. Patients
with a longer duration of psoriasis vulgaris (defined as>8 years) tended to have CHD [17].
Psoriasis disease characteristics and medications may also impact the clinical outcome of CHD
Table 3. Reported odds ratios (95% confidence intervals) of risk factors for coronary heart disease.
Odds ratio (95% conﬁdence interval)
Source Population Hypertension Dyslipidemia Diabetes mellitus
Kawano H[44] Hospital based population (Japan) 4.8 (3.8–5.95) 1.28 (1.00–1.62) 3.44 (2.50–4.75)
Iso H[45] General population (male, Japan) 2.1 (1.1–3.8) 2.5 (1.5–4.3) 1.0 (0.5–0.9)
Iso H[45] General population (female, Japan) 1.3 (0.6–2.8) 1.8 (0.9–3.4) 0.5 (0.1–2.1)
Armstrong AW[17] Hospital based population (US) 1.55 (1.36–1.77) 1.87 (1.66–2.12) 1.63 (1.42–1.88)
Medrano MJ[46] General population (Spain) 1.24 (0.88–1.73) 1.97 (1.42–2.73) 1.52 (1.0–2.33)
Shiba M (this study) Hospital based population (Japan) 7.78 (7.25–8.36) 2.35 (2.19–2.52) 2.86 (2.67–3.06)
doi:10.1371/journal.pone.0149316.t003
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in those with psoriasis [10, 48]. Substantial undertreatment of coronary risk factors is noted in
patients with severe psoriasis by Danish nationwide registry [49]. It is controversial whether
biological drugs for psoriasis vulgaris, e.g., TNF-α inhibitors and IL12/23 inhibitors, reduce the
risk for cardiovascular events [50–52]. Further population-based studies that consider psoriasis
characteristics/treatment, age, sex, smoking, etc. are required to generalize and verify that pso-
riasis is an independent risk factor for CHD in the Japanese population.
Conclusion
Psoriasis vulgaris was independently associated with CHD in a hospital-based population in
Japan.
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